title: Knockdown of prodynorphin gene prevents cognitive decline, reduces anxiety, and rescues loss of group 1 metabotropic glutamate receptor function in aging.
abstract: Expression of dynorphin, an endogenous opioid peptide, increases with age and has been associated with memory impairments in rats. In human, prodynorphin (Pdyn) gene polymorphisms might be linked to cognitive function in the elderly. Moreover, elevated dynorphin levels have been reported in postmortem samples from Alzheimer's disease patients. However, the cellular and molecular processes affected by higher dynorphin levels during aging remain unknown. Using Pdyn(-/-) mice, we observed significant changes in the function and expression of Group 1 metabotropic glutamate receptor (mGluR). Compared with age-matched wild-type (WT) littermates, we found increased expression of mGluR1α and mGluR5 in the hippocampus and cortex of old, but not young, Pdyn(-/-) mice. Increased Group 1 mGluR expression in aged Pdyn(-/-) mice was associated with enhanced mGluR-mediated long-term depression, a form of synaptic plasticity. Notably, whereas aged WT mice developed spatial and recognition memory deficits, aged Pdyn(-/-) mice performed similarly as young mice. Pharmacological treatments with 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide, a positive modulator of mGlu5 receptors, or norbinaltorphimine, an antagonist for dynorphin-targeted κ-opioid receptor, rescued memory in old WT mice. Conversely, mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine hydrochloride impaired spatial memory of old Pdyn(-/-) mice. Intact cognition in aged Pdyn(-/-) mice paralleled with increased expression of Group 1 mGluR-related genes Homer 1a and Arc. Finally, aged Pdyn(-/-) mice displayed less anxiety-related behaviors than age-matched WT mice. Together, our results suggest that elevated Pdyn expression during normal aging reduces mGluR expression and signaling, which in turn impairs cognitive functions and increases anxiety.
authors.affiliation: Douglas Mental Health University Institute, McGill University, Montreal, Quebec H4H 1R3, Canada.
authors.forename: Caroline
authors.initials: C
authors.lastname: Ménard
authors.forename: Yiu Chung
authors.initials: YC
authors.lastname: Tse
authors.forename: Chelsea
authors.initials: C
authors.lastname: Cavanagh
authors.forename: Jean-Guy
authors.initials: JG
authors.lastname: Chabot
authors.forename: Herbert
authors.initials: H
authors.lastname: Herzog
authors.forename: Christoph
authors.initials: C
authors.lastname: Schwarzer
authors.forename: Tak Pan
authors.initials: TP
authors.lastname: Wong
authors.forename: Rémi
authors.initials: R
authors.lastname: Quirion
mesh_terms: D000375:Aging / Q000502:physiology*; D000818:Animals; D001007:Anxiety / Q000188:drug therapy / Q000378:metabolism*; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D001589:Benzphetamine / Q000031:analogs & derivatives / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D003072:Cognition Disorders / Q000188:drug therapy; D004195:Disease Models, Animal; D004745:Enkephalins / Q000172:deficiency*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005106:Exploratory Behavior / Q000187:drug effects / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects / Q000235:genetics*; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D066298:In Vitro Techniques; D036881:Long-Term Synaptic Depression / Q000187:drug effects / Q000235:genetics; D008569:Memory Disorders / Q000188:drug therapy / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011498:Protein Precursors / Q000172:deficiency*; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors / Q000378:metabolism*; D021641:Recognition, Psychology / Q000187:drug effects / Q000502:physiology
chemical_list: C494553:3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; D001549:Benzamides; D000697:Central Nervous System Stimulants; D004745:Enkephalins; D018691:Excitatory Amino Acid Antagonists; D011498:Protein Precursors; D011720:Pyrazoles; D011725:Pyridines; D018094:Receptors, Metabotropic Glutamate; C104077:metabotropic glutamate receptor type 1; D001589:Benzphetamine; C008669:norbenzphetamine; C121465:6-methyl-2-(phenylethynyl)pyridine; C033660:preproenkephalin
references.citation: Behav Brain Res. 2008 Aug 22;191(2):235-45
references.pmid: 18471908
references.citation: Neuron. 2008 Apr 24;58(2):186-94
references.pmid: 18439404
references.citation: Behav Neurosci. 2011 Dec;125(6):836-47
references.pmid: 22122147
references.citation: J Neurosci. 2009 Apr 1;29(13):4293-300
references.pmid: 19339623
references.citation: Brain. 2007 Apr;130(Pt 4):1017-28
references.pmid: 17347252
references.citation: Neuropharmacology. 1997 Nov-Dec;36(11-12):1517-32
references.pmid: 9517422
references.citation: J Neurosci. 1992 Feb;12(2):425-9
references.pmid: 1346803
references.citation: Eur J Pharmacol. 2010 Aug 10;639(1-3):40-6
references.pmid: 20371241
references.citation: Pharmacol Biochem Behav. 1990 Feb;35(2):429-35
references.pmid: 1969641
references.citation: Neuropsychopharmacology. 2011 Mar;36(4):782-92
references.pmid: 21150906
references.citation: J Neurosci. 2008 Jan 30;28(5):1030-3
references.pmid: 18234881
references.citation: Trends Neurosci. 2007 Mar;30(3):111-8
references.pmid: 17234277
references.citation: Neuropharmacology. 2013 Jan;64:65-73
references.pmid: 22732443
references.citation: Trends Pharmacol Sci. 2011 Jan;32(1):43-52
references.pmid: 21129790
references.citation: Neuroscience. 1998 Jul;85(2):375-82
references.pmid: 9622237
references.citation: Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11686-91
references.pmid: 21709248
references.citation: J Pharmacol Exp Ther. 2007 Dec;323(3):838-45
references.pmid: 17823306
references.citation: Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):125-37
references.pmid: 11165379
references.citation: Brain Res. 1991 Oct 25;562(2):243-50
references.pmid: 1685342
references.citation: Am J Geriatr Psychiatry. 2001 Spring;9(2):113-35
references.pmid: 11316616
references.citation: Pharmacol Ther. 2009 Sep;123(3):353-70
references.pmid: 19481570
references.citation: Behav Pharmacol. 2008 May;19(3):225-34
references.pmid: 18469540
references.citation: J Neurosci. 2000 Jan 1;20(1):8-21
references.pmid: 10627576
references.citation: Proc Natl Acad Sci U S A. 1989 Apr;86(8):2948-51
references.pmid: 2565040
references.citation: Eur J Pharmacol. 1996 Jun 20;307(1):7-14
references.pmid: 8831097
references.citation: Learn Mem. 2006 Mar-Apr;13(2):178-86
references.pmid: 16585793
references.citation: J Neurosci. 1997 Jul 1;17(13):5196-205
references.pmid: 9185557
references.citation: Behav Brain Res. 2005 Jun 20;161(2):254-62
references.pmid: 15922052
references.citation: Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6055-60
references.pmid: 17389377
references.citation: Molecules. 2011 Mar 02;16(3):2097-106
references.pmid: 21368721
references.citation: Learn Mem. 1999 Mar-Apr;6(2):138-52
references.pmid: 10327239
references.citation: J Neurosci. 1995 Jun;15(6):4602-11
references.pmid: 7540680
references.citation: Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16697-702
references.pmid: 20823230
references.citation: J Neurosci. 2009 Mar 25;29(12):3676-84
references.pmid: 19321764
references.citation: PLoS One. 2012;7(1):e28666
references.pmid: 22238580
references.citation: Neuropsychopharmacology. 2009 Feb;34(3):775-85
references.pmid: 18800067
references.citation: Neuropsychopharmacology. 2009 Aug;34(9):2057-71
references.pmid: 19295507
references.citation: J Neurosci. 2012 Jan 25;32(4):1488-95
references.pmid: 22279233
references.citation: Behav Brain Res. 2004 Aug 31;153(2):471-80
references.pmid: 15265645
references.citation: J Endocrinol. 2006 Jun;189(3):617-27
references.pmid: 16731792
references.citation: Nat Neurosci. 2005 Dec;8(12):1657-9
references.pmid: 16286930
references.citation: Front Aging Neurosci. 2012 Sep 12;4:15
references.pmid: 22988437
references.citation: Behav Brain Res. 1993 Nov 30;57(2):155-62
references.pmid: 7906946
references.citation: J Neurophysiol. 1994 Oct;72(4):1697-705
references.pmid: 7823095
references.citation: Psychol Rev. 1992 Apr;99(2):195-231
references.pmid: 1594723
references.citation: Neuroscience. 1998 Apr;83(3):669-80
references.pmid: 9483551
references.citation: Life Sci. 1978 Mar;22(10):897-906
references.pmid: 642704
references.citation: Neurobiol Aging. 2007 Nov;28(11):1700-8
references.pmid: 16914231
references.citation: Nature. 1993 Jun 3;363(6428):451-4
references.pmid: 8099201
references.citation: Behav Brain Res. 2013 Mar 15;241:27-31
references.pmid: 23228523
references.citation: J Endocrinol. 1999 Jan;160(1):1-12
references.pmid: 9854171
references.citation: BMC Pharmacol. 2012 May 29;12:5
references.pmid: 22642416
references.citation: Front Pharmacol. 2012 Oct 12;3:182
references.pmid: 23091460
references.citation: Neuropharmacology. 2009 Oct-Nov;57(5-6):531-8
references.pmid: 19627999
references.citation: Annu Rev Neurosci. 1999;22:105-22
references.pmid: 10202533
references.citation: Neuron. 2010 Feb 25;65(4):445-59
references.pmid: 20188650
references.citation: J Neurosci. 2010 Mar 10;30(10):3813-25
references.pmid: 20220016
references.citation: Neurobiol Aging. 2004 Nov-Dec;25(10):1343-7
references.pmid: 15465632
references.citation: J Neural Transm (Vienna). 2009 Jul;116(7):897-903
references.pmid: 19468819